Explore This Research Award in CaptureIQ
Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.
Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- ICHOR MEDICAL SYSTEMS, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Q2Z1EV1XZWX9
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
DESCRIPTION (Provided by Applicant):The primary goal of the project is the
development of automated equipment suitable for the clinical application of
Electroporation Therapy (EPT). This system will provide the foundation for
clinical implementation of Ichor's proprietary therapy, which has shown promise
for treatment of solid tumors in the pancreas, head & neck, liver, and brain.
Preclinical studies performed by Ichor confirmed data reported in the
literature characterize the cytotoxic effects of EPT. However, these studies
also suggest that, unlike traditional EPT approaches, unique features of this
therapy make it highly selective for malignant cells. Thus, the technology
potentially offers a method of treatment for locally advanced tumors with
margins that extend into surrounding tissues.
Feasibility of the proposed EPT system will be established by designing,
constructing, and testing a microprocessor-based switching apparatus. This
system will directly control delivery of electroporation pulses to an electrode
array implanted in the patient. Research will focus on the components,
architecture, and control system best suited for safe application of the unique
electrical signals characteristic of electroporation. After feasibility has
been confirmed, integration of the switching apparatus with pulse generation
and control means will provide an EPT system appropriate for multi-center
clinical studies and eventual commercial use.
PROPOSED COMMERCIAL APPLICATION:
Electroporation Therapy with bleomycin (EPT-B) has potential as a locoregional treatment for
both primary and secondary tumors. In both preclinical and early phase clinical studies,
EPT-B has shown significant anti-tumor effect in a variety of tumor types. It appears that
EPT-B could be clinically appropriate for several cancers including head & neck, pancreatic,
liver, and brain. The proposed research will focus on the development of an Electroporation
Therapy system appropriate for commercial clinical use.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Research funding history
30 SBIR/STTR records share this UEI (1995–2011). Reported award amounts total $13,021,905. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services, Department of Defense
Agency intelligence
Department of Health and Human Services
Back to SBIR/STTR Research Awards